Orexo develops improved pharmaceuticals addressing unmet needs, foremost within the growing space of mental illness and substance use disorders. To achieve better treatment results and increase access to care, Orexo also works with evidence-based digital therapies. The products are commercialized by Orexo in the US or via partners worldwide.
Explore more about our business
Orexo’s own sales force commercializes pharmaceuticals in the US. Today US Pharma consists of the lead product ZUBSOLV®, for the treatment of opioid use disorder.
HQ & Pipeline
Orexo develops improved drugs based on well-known substances combined with innovative proprietary drug delivery technologies, such as amorphOX®.
Our evidence-based digital therapies grounded in cognitive behavioral therapy techniques, offer increase access to care and improve treatment outcomes.